Non-Hodgkin Lymphoma | Specialty

Dr. Peter Martin on Future Treatment Approaches in Mantle Cell Lymphoma

March 15th 2016

Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).

CAR T-cell Therapies Effective Across Hematologic Malignancies

March 2nd 2016

Chimeric antigen receptor-modified T-cell therapies continue to demonstrate promising signs of efficacy for patients with hematologic malignancies, including those with acute lymphoblastic leukemia and non-Hodgkin lymphoma.

FDA Approves Obinutuzumab for Follicular Lymphoma

February 26th 2016

The FDA approved obinutuzumab (Gazyva) plus bendamustine followed by obinutuzumab alone for the treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.

Blinatumomab Nears 70% Response Rate in Non-Hodgkin Lymphoma

February 18th 2016

The anti-CD19 agent blinatumomab (Blincyto) induced a response rate of 69% in patients with non-Hodgkin Lymphoma.

SYK Inhibitor Shows Promise in CLL

February 18th 2016

Entospletinib (GS-9973) has shown early promise as a treatment for pretreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCL

February 17th 2016

Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

Tackling Challenging Patient Populations in DLBCL

January 21st 2016

Kathryn Kolibaba, MD, discusses the significance of the PYRAMID and other studies, and how she hopes the treatment paradigm for diffuse large b-cell lymphoma will evolve in the future.

Future Strategies in the Treatment of Follicular Lymphoma

January 18th 2016

Novel Treatment Approaches in Follicular Lymphoma

January 18th 2016

Combining Targeted and Immunotherapeutic Agents in FL

January 18th 2016

The Role of Ibrutinib in Follicular Lymphoma

January 18th 2016

Monoclonal Antibodies in Follicular Lymphoma

January 18th 2016

Treating Relapsed/Refractory Follicular Lymphoma

January 18th 2016

First-Line Therapeutic Options in Follicular Lymphoma

January 18th 2016

'Watch and Wait' Versus Therapy Initiation in Follicular Lymphoma

January 18th 2016

Follicular Lymphoma Risk Stratification

January 18th 2016

The Biology of Follicular Lymphoma

January 18th 2016

Expert Discusses Emerging Agents and the Future of Follicular Lymphoma

January 18th 2016

John P. Leonard, MD, discusses the potential for lenalidomide, idelalisib, and ibrutinib in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.

Dr. Frederick Locke on KTE-C19 for Refractory NHL

January 13th 2016

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses KTE-C19 for the treatment of refractory aggressive non-Hodgkin lymphoma (NHL).